Abstract 4363872: Acoramidis Improved Clinical Outcomes, Function, Quality of Life and NT-proBNP in Patients With Transthyretin Amyloid Cardiomyopathy Regardless of Atrial Fibrillation Status at Baseline
Brett W. Sperry(Saint Luke's Hospital), Francesco Cappelli(National Institute of Optics), Deirdre Mooney(Providence Sacred Heart Medical Center), Ahmad Masri(Oregon Health & Science University), Brian Drachman(Penn Presbyterian Medical Center), Martha Grogan(Mayo Clinic in Arizona), Masatake Kobayashi(Tokyo Medical University), Daniel P. Judge(Medical University of South Carolina), Olakunle O. Akinboboye(Allegheny College), José Nativi-Nicolau(Jacksonville College), Christopher S. Chen(Inspire), Jean‐François Tamby(Medical University of South Carolina), Adam Castaño(Columbia University Irving Medical Center), Jonathan C. Fox(Fluidigm (United States)), Richard Cheng(University of Washington)
Cited by 0
Related Papers
Geometric Control of Cell Life and Death
|Science|1997|4.7k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy
|New England Journal of Medicine|2018|2.8k
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
|Circulation|2016|2k
Demonstration of mechanical connections between integrins, cytoskeletal filaments, and nucleoplasm that stabilize nuclear structure
|Proceedings of the National Academy of Sciences|1997|1.6k